Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro

International Journal of Cancer

Volumn 119, Issue 12, 2006, Pages 2948-2957

  Li, Xiao ^a   Jin, Ningyi ^a   Mi, Zhiqiang ^a   Lian, Hai ^a   Sun, Lili ^b   Li, Xuemei ^a   Zheng, Hongling ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Apoptin; Cancer; Fowlpox virus vector; Gene therapy

Indexed keywords

APOPTIN; BETA ACTIN; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTIN GENE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL STRAIN HEPG2; CIRCOVIRIDAE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; FOWLPOX VIRUS; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR CELL; VIRAL GENE THERAPY; VIRUS RECOMBINANT; WILD TYPE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CAPSID PROTEINS; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; FEMALE; FOWLPOX VIRUS; GENE EXPRESSION; GENE THERAPY; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFECTION;

EID: 33751574255     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22215     Document Type: Article

References (55)

1. Danen-Van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JH, Backendorf C, Quax PH, Van der Eb AJ, Noteborn MH. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997;94:5843-7.
2. Jeurissen SH, Wagenaar F, Pol JM, van der Eb AJ, Noteborn MH. Chicken anemia virus causes apoptosis of thymocytes after in vivo infection and of cell lines after in vitro infection. J Virol 1992;66:7383-8.
3. Rohn JL, Noteborn MH. The viral death effector apoptin reveals tumor-specific processes. Apoptosis 2004;9:315-22.
4. Wang QM, He FC. [Molecular mechanism of specific induction of apoptosis in tumor cells by apoptin]. Ai Zheng 2005;24:509-12.
5. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006;5:10-19.
6. Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb AJ, Noteborn MH. Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res 1995;55:486-9.
7. Zhuang SM, Shvarts A, Jochemsen AG, van Oorschot AA, van der Eb AJ, Noteborn MH. Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis. Carcinogenesis 1995;16:2939-44.
8. Danen-van Oorschot AA, den Hollander AI, Takayama S, Reed JC, van der Eb AJ, Noteborn MH. BAG-I inhibits p53-induced but not apoptin-induced apoptosis. Apoptosis 1997;2:395-402.
9. Danen-Van Oorschot AA, Zhang Y, Erkeland SJ, Fischer DF, van der Eb AJ, Noteborn MH. The effect of Bcl-2 on Apoptin in 'normal' vs transformed human cells. Leukemia 1999; (13 Suppl 1):S75-S77.
10. Burek M, Maddika S, Burek CJ, Daniel PT, Schulze-Osthoff K, Los M. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene 2006;25:2213-22.
11. Danen-Van Oorschot AA, van der Eb AJ, Noteborn MH. BCL-2 stimulates Apoptin-induced apoptosis. Adv Exp Med Biol 1999;457:245-9.
12. Danen-van Oorschot AA, van Der Eb AJ, Noteborn MH. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol 2000;74:7072-8.
13. van der Eb MM, Pietersen AM, Speetjens FM, Kuppen PJ, van de Velde CJ, Noteborn MH, Hoeben RC. Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther 2002;9:53-61.
14. Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MH, Cornelis JJ. Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther 2001;8:958-65.
15. Pietersen AM, van der Eb MM, Rademaker HJ, van den Wollenberg DJ, Rabelink MJ, Kuppen PJ, van Dierendonck JH, van Ormondt H, Masman D, van de Velde CJ, van der Eb AJ, Hoeben RC et al. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther 1999;6:882-92.
16. Gottesman MM. Cancer gene therapy: an awkward adolescence. Cancer Gene Ther 2003;10:501-8.
17. Scholl SM, Michaelis S, McDermott R. Gene therapy applications to cancer treatment. J Biomed Biotechnol 2003;2003:35-47.
18. Ferber D. Gene therapy. Safer and virus-free? Science 2001;294:1638-42.
19. Solomon MF, Ramshaw IA, Simeonovic CJ. Recombinant fowlpox virus for in vitro gene delivery to pancreatic islet tissue. Immunol Cell Biol 2005;83:615-25.
20. Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 2005;4:63-76.
21. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000;6:24-33.
22. Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001;61:3725-34.
23. Jiang W, Jin N, Cui S, Li Z, Zhang L, Zhang H, Wang H, Han W. Construction and characterization of recombinant fowlpox virus coexpressing HIV-1(CN) gp120 and IL-2. J Virol Methods 2005;130:95-101.
24. Guan GF, Jin NY, Mi ZQ, Li X, Lian H, Jin CS, Sun LL, Wen LJ. Construction of the nucleic vaccine pVVP3L-18HN and its antitumor effect on human laryngeal carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2005;40:566-70.
25. Jia L, Peng D, Zhang Y, Liu H, Liu X. Construction, genetic stability and protective efficacy of recombinant fowlpox virus expressing hemagglutinin gene of H5N1 subtype avian influenza virus. Wei Sheng Wu Xue Bao 2003;43:722-7.
26. Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J, Barrett AD, Monath TP. Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 1999;257:363-72.
27. Kestler J, Neeb B, Struyf S, Van Damme J, Cotmore SF, D'Abramo A, Tattersall P, Rommelaere J, Dinsart C, Cornelis JJ. cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 1999;10:1619-32.
28. Yang YP, Kuo HS, Tsai HD, Peng YC, Lin YL The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone. Breast Cancer Res 2005;7:R19-R27.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
30. Steinwaerder DS, Carlson CA, Lieber A. Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes. Mol Ther 2001;4:211-16.
31. Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005;5:12.
32. Sun YC, Jin NY, Mi ZQ, Li X, Lian H, Li P. Induction of apoptosis in human hepatoma cell line SMMC7721 by Newcastle disease virus HN gene. Zhonghua Zhong Liu Za Zhi 2005;27:279-82.
33. + cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 2004;11:665-80.
34. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2003;9:2973-80.
35. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M, Laidlaw SM, Peto T, Skinner MA, Gilbert SC, Hill AV. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in nonimmune volunteers. Vaccine 2006;24:3026-34.
36. Cohen JJ. Apoptosis. Immunol Today 1993;14:126-30.
37. Candal E, Anadon R, DeGrip WJ, Rodriguez-Moldes I. Patterns of cell proliferation and cell death in the developing retina and optic tectum of the brown trout. Brain Res Dev Brain Res 2005;154:101-19.
38. Renvoize C, Biola A, Pallardy M, Breard J. Apoptosis: identification of dying cells. Cell Biol Toxicol 1998;14:111-20.
39. Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005;57:187-215.
40. Oro C, Jans DA. The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr Drug Targets 2004;5:179-90.
41. Schoop RA, Kooistra K, Baatenburg De Jong RJ, Noteborn MH. Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line. Int J Cancer 2004;109:38-42.
42. Noteborn MH, Zhang YH, van der Eb AJ. Apoptin specifically causes apoptosis in tumor cells and after UV-treatment in untransformed cells from cancer-prone individuals: a review. Mutat Res 1998;400:447-55.
43. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996;10:1945-52.
44. Nielsen LL, Maneval DC. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998;5:52-63.
45. Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 1995;6:155-64.
46. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-91.
47. Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, Tang DB, Vaughn DW, Mason PW, Shope RE. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus - poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 2000;19:483-91.
48. Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA, Kauffman EB, Wirtz RA, De Taisne C, Hui GS, Chang SP, Church P et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 1996;64:3833-44.
49. De Rose R, Chea S, Dale CJ, Reece J, Fernandez CS, Wilson KM, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Sullivan MT, Kent SJ. Subtype AE HIV-1 DNA and recombinant fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 2005;23:1949-56.
50. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-31.
51. de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, Burke D, Evans TG, Corey L, Keefer MC. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004;22:704-13.
52. Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, Plotkin S. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996;14:428-34.
53. Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM, Zahradnik J, Pincus S, Berencsi K, Cox WI et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999;180:843-6.
54. Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, Lezhava T, Williams WW. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-8.
55. Soruri A, Fayyazi A, Gieseler R, Schlott T, Runger TM, Neumann C, Peters JH. Specific autologous anti-melanoma T cell response in vitro using monocyte-derived dendritic cells. Immunobiology 1998;198:527-38.